<DOC>
	<DOC>NCT01315249</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy and safety/tolerability of indacaterol and glycopyrronium (QVA149) (fixed-dose combination) with fluticasone/salmeterol over a 26-week period in patients with moderate to severe COPD.</brief_summary>
	<brief_title>QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Smoking history of at least 10 pack years Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) (moderatetosevere as classified by the Global Initiative for Chronic Obstructive Lung Disease [GOLD] Guidelines, 2009) Postbronchodilator Forced Expiratory Volume in 1 second (FEV1) &gt;40% and &lt; 80% of the predicted normal value and postbronchodilator FEV1/Forced Vital Capacity (FVC) &lt;70% Patients who have had a COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or intravenous) or hospitalization in the last year. Patients requiring long term oxygen therapy on a daily basis for chronic hypoxemia. Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1. Patients with concomitant pulmonary disease Patients with a history of asthma Any patient with lung cancer or a history of lung cancer (within last 5 years) Patients with a history of certain cardiovascular comorbid conditions</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>QVA149</keyword>
	<keyword>indacaterol</keyword>
	<keyword>NVA237</keyword>
	<keyword>COPD</keyword>
	<keyword>fluticasone/salmeterol</keyword>
</DOC>